1. The Food and drug Administration. FDA approves ruxolitinib for chronic graft-versus-host disease. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ruxolitinib-chronic-graft-versus-host-disease.
2. Ruxolitinib versus standard therapy for the treatment of polycythemia vera;Vannucchi;N. Engl. J. Med.,2015
3. Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis;Mesa;IDrugs,2010
4. Targeting myeloproliferative neoplasms with JAK inhibitors;Pardanani;Curr. Opin. Hematol.,2011
5. Ruxolitinib Cream Prescribing Information,2022